Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00115076
Status:
COMPLETED
Last Update Posted:
2021-02-08
First Post:
2005-06-20
Brief Title:
Study of the Drug Efalizumab Raptiva for Adult Patients With Moderate to Severe Plaque Psoriasis
Sponsor:
Rockefeller University
Organization:
Rockefeller University
Study Overview
Official Title:
A Phase IIIB Study to Evaluate the Mechanism of Action of 10 mgkg Subcutaneously Administered Efalizumab in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Our laboratory is studying a skin disease known as psoriasis The purpose of this protocol is to study the action and the effects of Efalizumab on psoriasis This medication has been studied extensively and has been found to be effective and safe in the treatment of psoriasis The eligible patient will have 10 of hisher body surface area involved with psoriasis vulgaris
Detailed Description:
The eligible patient will receive the drug Efalizumab weekly for 12 weeks by injection The patient will be seen weekly for 12 weeks and every other week for the 12 weeks of follow up At those visits the patient can expect that a physical and skin exam will be done At specific weeks blood work will be drawn clinical photography taken and a skin biopsy done Two types of skin biopsies will be done after local anesthesia has been administered One is a punch biopsy where a small piece of skin will be taken the approximate size of a pencil eraser The second type of skin biopsy is shave biopsy where a postage sized piece of skin will be taken
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None